Literature DB >> 9326618

Insulin and insulin-like growth factor-I acutely inhibit surface translocation of growth hormone receptors in osteoblasts: a novel mechanism of growth hormone receptor regulation.

K C Leung1, M J Waters, I Markus, W R Baumbach, K K Ho.   

Abstract

We previously have demonstrated that insulin and insulin-like growth factor-I (IGF-I) down-regulate growth hormone (GH) binding in osteoblasts by reducing the number of surface GH receptors (GHRs). The present study was undertaken to investigate the mechanism of GHR down-regulation. Treatment with 5 nM insulin or IGF-I for 18 hr significantly decreased surface GH binding to 26.4 +/- 2.9% and 23.0 +/- 2.7% of control (mean +/- SE; P < 0.05), respectively. No corresponding reductions in the mRNA level and total cellular content of GHR were found, nor was the rate of receptor internalization affected. The effects on GHR translocation were assessed by measuring the reappearance of GH binding of whole cells after trypsinization to remove the surface receptors. GH binding of control cultures significantly increased (P < 0.05) over 2 hr after trypsinization, whereas no recovery of binding activity was detected in insulin and IGF-I-treated cultures, indicating that GHR translocation was impaired. Studies on the time course of GHR down-regulation revealed that surface GH binding was reduced significantly by 3-hr treatment (P </= 0.0005), whereas GHR translocation was completely abolished by 75-90 min with insulin and IGF-I. The inhibition of receptor translocation by insulin, but not IGF-I, was attenuated by wortmannin. In conclusion, insulin and IGF-I down-regulated GH binding in osteoblasts by acutely impairing GHR translocation, with their effects exerted through distinct postreceptor signaling pathways.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9326618      PMCID: PMC23473          DOI: 10.1073/pnas.94.21.11381

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  A personal history of the origin of the somatomedin hypothesis and recent challenges to its validity.

Authors:  W H Daughaday
Journal:  Perspect Biol Med       Date:  1989       Impact factor: 1.416

2.  The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling pathways.

Authors:  S A Coolican; D S Samuel; D Z Ewton; F J McWade; J R Florini
Journal:  J Biol Chem       Date:  1997-03-07       Impact factor: 5.157

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Essential role of phosphatidylinositol 3-kinase in insulin-induced glucose transport and antilipolysis in rat adipocytes. Studies with a selective inhibitor wortmannin.

Authors:  T Okada; Y Kawano; T Sakakibara; O Hazeki; M Ui
Journal:  J Biol Chem       Date:  1994-02-04       Impact factor: 5.157

5.  Genomic sequencing.

Authors:  G M Church; W Gilbert
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

6.  Insulin-like growth factor binding proteins-2 and -3 stimulate growth hormone receptor binding and mitogenesis in rat osteosarcoma cells.

Authors:  M C Slootweg; C Ohlsson; J P Salles; C P de Vries; J C Netelenbos
Journal:  Endocrinology       Date:  1995-10       Impact factor: 4.736

7.  Human growth hormone-stimulated growth of human cultured lymphocytes (IM-9) and its inhibition by phorbol diesters through down-regulation of the hormone receptors. Possible involvement of phosphorylation of a 55,000 molecular weight protein associated with the receptor in the down-regulation.

Authors:  K Suzuki; S Suzuki; Y Saito; H Ikebuchi; T Terao
Journal:  J Biol Chem       Date:  1990-07-05       Impact factor: 5.157

8.  Vanadate down-regulates cell surface insulin and growth hormone receptors and inhibits insulin receptor degradation in cultured human lymphocytes.

Authors:  K Torossian; D Freedman; I G Fantus
Journal:  J Biol Chem       Date:  1988-07-05       Impact factor: 5.157

9.  Mitogen-activated protein kinase kinase inhibition does not block the stimulation of glucose utilization by insulin.

Authors:  D F Lazar; R J Wiese; M J Brady; C C Mastick; S B Waters; K Yamauchi; J E Pessin; P Cuatrecasas; A R Saltiel
Journal:  J Biol Chem       Date:  1995-09-01       Impact factor: 5.157

10.  Intracellular processing of growth hormone receptors by adipocytes in primary culture.

Authors:  P Roupas; A C Herington
Journal:  Mol Cell Endocrinol       Date:  1988-05       Impact factor: 4.102

View more
  5 in total

Review 1.  Acromegaly pathogenesis and treatment.

Authors:  Shlomo Melmed
Journal:  J Clin Invest       Date:  2009-11-02       Impact factor: 14.808

2.  A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis.

Authors:  Emmanuel Somm; Nicolas Bonnet; Alberto Martinez; Philip M H Marks; Verity A Cadd; Mark Elliott; Audrey Toulotte; Serge L Ferrari; René Rizzoli; Petra S Hüppi; Elaine Harper; Shlomo Melmed; Richard Jones; Michel L Aubert
Journal:  J Clin Invest       Date:  2012-08-01       Impact factor: 14.808

3.  Mechanisms Underlying the Synergistic Action of Insulin and Growth Hormone on IGF-I and -II Expression in Grass Carp Hepatocytes.

Authors:  Quan Jiang; Jin Bai; Mulan He; Karen W Y Yuen; Anderson O L Wong
Journal:  Front Endocrinol (Lausanne)       Date:  2018-06-21       Impact factor: 5.555

Review 4.  Growth Hormone Receptor Regulation in Cancer and Chronic Diseases.

Authors:  Ger J Strous; Ana Da Silva Almeida; Joyce Putters; Julia Schantl; Magdalena Sedek; Johan A Slotman; Tobias Nespital; Gerco C Hassink; Jan A Mol
Journal:  Front Endocrinol (Lausanne)       Date:  2020-11-18       Impact factor: 5.555

5.  Estrogens regulate the hepatic effects of growth hormone, a hormonal interplay with multiple fates.

Authors:  Leandro Fernández-Pérez; Borja Guerra; Juan C Díaz-Chico; A Flores-Morales
Journal:  Front Endocrinol (Lausanne)       Date:  2013-06-03       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.